- Datum30.06.2026
- Uhrzeit10:00 - 12:00 Uhr
- Veranstalter
stock3
Alumis Inc. Chart inkl. Chartanalyse

Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen

Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Société Générale | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Wertentwicklung (Nasdaq)
Passender Service zu Alumis Inc.
Webinar zu Alumis Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,760-30,600
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Alumis Inc.
Termine von Alumis Inc.
Beschreibung
Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.
